HCA-7 Colony 29

2091238, human colon, Epithelial

• UNSPSC Code: 41106514

Properties

• product name: HCA-7 Colony 29, 02091238
• biological source: human colon
• growth mode: Adherent
• karyotype: Near Diploid
• morphology: Epithelial
• products: Expresses Cox-2
• receptors: EGF. Parent HCA-7 cell line: wildtype APC. Known mutations:Parent HCA-7 cell line: RER phenotype, p53
• technique(s): cell culture | mammalian: suitable
• relevant disease(s): cancer
• shipped in: dry ice
• storage temp.: −196°C

Description

Cell Line Origin

Human Colon Carcinoma (subpopulation isolated from the HCA-7 cell line)

Cell Line Description

The human colon cancer cell line, HCA-7 Colony 29 expresses Cox-2. An interesting feature of this cell line is that it forms polarised epithelial sheets which allows examination of the trafficking and release of biomolecules in vitro. Cyclooxygenases (COXs) are key enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids. It has been found that colonic polyps and cancers overexpress Cox-2 and that the inhibition of this enzyme by nonsteroidal anti-inflammatory drugs decreases the risk of colonic neoplasia. This cell line is useful for studying the role of Cox-2 in cancer cell biology and the investigation of colorectal epithelial cell polarity. Imperial College Innovations has stated that this cell line is not to be supplied to commercial organisations.

DNA Profile

STR-PCR Data: Amelogenin: X
CSF1PO: 11,14
D13S317: 9
D16S539: 10,11
D5S818: 8,12
D7S820: 11,12
THO1: 6,7
TPOX: 8,10
vWA: 14,16

Culture Medium

DMEM + 10% FBS + 2mM L-Glutamine + 110mg/L Sodium Pyruvate (NaP).

Subculture Routine

Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 1-2x10,000 cells/cm² using 0.05% trypsin/EDTA; 5% CO₂; 37°C.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Disclaimer

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.